Serum Institute Of India Issues Clarification Over Reports Of COVISHIELD Availability In 73 Days

By OB Bureau On Aug 23, 2020

Pune: Serum Institute of India (SII), on Sunday, issued a clarification that the current claims over commercialising COVISHIELD’s availability in 73 days, in the media is completely false and conjectural.

The official handle of the institute took to Twitter to issue the clarification.

We would like to clarify that the current media claim on COVISHIELD's availability in 73 days is misleading.

Phase-3 trials are still underway. We will officially confirm it’s availability.

Read clarification statement here – https://t.co/FvgClzcnHr #SII #COVID19 #LatestNews pic.twitter.com/mQWrqgbzO4

— SerumInstituteIndia (@SerumInstIndia) August 23, 2020

“Presently, the government has granted us permission to only manufacture the vaccine and stockpile it for future use. COVISHIELD will be commercialised once the trials are proven successful and all the requisite regulatory approvals are in place,” said the notice by SII.

“The phase-3 trials for the Oxford-AstraZeneca vaccine, are still underway. And only once the vaccine is proven immunogenic and efficacious, SII will confirm its availability, officially.”